Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new ...

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement ...

After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...